Actively Recruiting
Local Cecal Cancer - Optimization of Surgical Treatment
Led by Moscow Clinical Scientific Center · Updated on 2023-11-18
200
Participants Needed
1
Research Sites
226 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine the clinical efficacy, safety, and oncologic outcomes of ileocecal resection (ICR) with D3 lymphadenectomy compared to standard right hemicolectomy(RHC) for cecal cancer.
CONDITIONS
Official Title
Local Cecal Cancer - Optimization of Surgical Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least 18 years of age
- ECOG performance status of 0 to 2
- Histologically confirmed adenocarcinoma of the colon
- Clinical tumor stage T1 to T3 with node positive disease and no distant metastasis (M0)
- Physical status classified as ASA I, II, III, or IV
- Provided written informed consent to participate
You will not qualify if you...
- Presence of synchronous or metachronous malignancy
- Locally advanced tumor with stage greater than T3
- Presence of distant metastases (M1)
- Tumor complications such as obstruction or perforation
- Prior neoadjuvant chemotherapy
- Medical contraindications that prevent surgical treatment
- Pregnancy or breastfeeding
- Medical or psychiatric conditions that impair ability to consent or follow the study protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Moscow Clinical Scientific Center
Moscow, Russia
Actively Recruiting
Research Team
I
Igor Matveev
CONTACT
M
Mikhail Danilov
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here